MedTrace Logo

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals

NCT02568332 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-10-11

No results posted yet for this study

Summary

This study is aimed at assessing the safety of candidate Hepatitis C (Hep C) vaccines AdCh3NSmut1 and MVA-NSmut when administered to Human Immunodeficiency Virus (HIV) seropositive individuals. This study also aims to assess the cellular immune response generated by these vaccines when administered as mentioned above.

Conditions

  • Hepatitis C Infection

Interventions

BIOLOGICAL

AdCh3NSmut1

Genetic vaccine against Hepatitis C virus infection

BIOLOGICAL

MVA-NSmut

Genetic vaccine against Hepatitis C virus infection

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • ReiThera Srl

    collaborator INDUSTRY

  • Cantonal Hospital of St. Gallen

    collaborator OTHER

  • St. James's Hospital, Ireland

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Lucy Dorrell, Prof · University of Oxford

  • Ellie Barnes, Prof · University of Oxford

  • Matthias Hoffmann, Dr · Cantonal Hospital of St. Gallen

  • Colm Bergin, Prof · St. James's Hospital, Ireland

  • Pietro Vernazza, Prof · Cantonal Hospital of St. Gallen

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-21
Primary Completion
2017-01-26
Completion
2017-10-31

Countries

  • Ireland
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02568332 on ClinicalTrials.gov